NCT03400306 is a Phase 1 clinical trial of Veliparib, capsule in Cancer - Ovarian, sponsored by AbbVie.

Who is sponsoring NCT03400306?

NCT03400306 is sponsored by AbbVie.

What drugs are being tested in NCT03400306?

Interventions in NCT03400306: Veliparib, capsule, Veliparib, tablet, Carboplatin, Paclitaxel.

What condition does NCT03400306 study?

NCT03400306 studies Cancer - Ovarian.

Is NCT03400306 still recruiting?

NCT03400306 is currently withdrawn. Last updated 8 December 2021.

Last reviewed 2021-12-08 · How we verify

NCT03400306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Withdrawn Phase 1 Last updated 8 December 2021

What this trial tests

Phase 1 trial testing Veliparib, capsule in Cancer - Ovarian. Withdrawn.

Timeline

15 November 2021

Primary endpoint
16 November 2021

16 November 2021

Quick facts

Lead sponsor	AbbVie
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Start date	15 November 2021
Primary completion	16 November 2021
Estimated completion	16 November 2021

Drugs / interventions tested

Veliparib, capsule — full drug profile →
Veliparib, tablet
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Cancer - Ovarian — all drugs for Cancer - Ovarian →

Sponsor

AbbVie — full company profile →

Who can join

Adults 18 to 99, female only, with Cancer - Ovarian. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer - Ovarian

Currently open trials in the same condition.

NCT07290309 — Survivors Uniting for Remote Guided Exercise · NA · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03400306 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 8 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03400306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing